IASLC WCLC

IASLC Meetings and Webinars

IASLC Meetings and Conference

Founded in 1972, the International Association for the Study of Lung Cancer (IASLC) is an international organization of more than 8,000 lung cancer specialists from 100+ countries. IASLC members work towards developing and promoting the study of etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer. IASLC’s mission is to enhance the understanding and education of lung cancer to scientists, members of the medical community and the public. In addition to the annual meeting, the IASLC publishes the Journal of Thoracic Oncology, a prized resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.The IASLC World Conference on Lung Cancer (WCLC) is the largest international gathering in the field of lung cancer and thoracic oncology. With a stellar scientific program and well known faculty, WCLC highlights the most advanced treatments, clinical trials and studies in thoracic oncology and lung cancer.

WCLC2026

I acknowledge that my data including name, job title, organization, city/country and email address may be shared with each supporter whose virtual symposium I may attend during the Conference so that they may send me marketing communications and further information.

I acknowledge that my data including name, job title, organization, city/country and email address may be shared with each exhibitor whose virtual exhibit listing I may visit during the Conference so that they may send me marketing communications and further information.IASLC follows the European Union’s General Data Protection Regulation (GDPR) for the collection, use, disclosure, and transfer of data. IASLC would like to support exhibitors and supporters by providing nominative data including your full name and email address if you agree.If you prefer not to share your information, please click "Continue".

PL02.06. Primary Results from Phase 3 EVOKE-03/KEYNOTE D46: Sacituzumab Govitecan + Pembrolizumab in PD-L1 TPS ≥50% Metastatic NSCLC

Click Here to Go Back to the Main Session

PL02. Presidential Symposium 1 Including Lectureship Award Presentations

Join the event!